Background: Globally, coronavirus disease 2019 (Cov-19) has resulted in the confinement of nearly three billion people and its management considered the trend topic. Lupus nephritis (LN) is the most common and serious manifestation of systemic lupus erythematousus (SLE). Clinical picture of Cov-19 in LN patients is often complicated by bacterial infections or thrombotic events, unless the prognosis of lupus nephritis remains unsatisfactory. Conventional clinical parameters including creatinine clearance, proteinuria, urine sediments, anti-dsDNA and complement levels are not sensitive or specific enough for detecting ongoing Cov-19 infection activity in lupus kidneys and early relapse of nephritis. Thus, novel biomarkers are necessary to enhance diagnostic accuracy and sensitivity of renal disease, prognostic stratification, monitoring of treatment response and detection of early renal flares.